HI
TBPH icon

HBK Investments’s Theravance Biopharma TBPH Stock Holding History

HBK Investments’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-24,922
Closed -$565K – 1015
2019
Q1 		$565K Buy
+24,922
New +$632K 0.01% 799
2016
Q3 		– Sell
-9,598
Closed -$218K – 1007
2016
Q2 		$218K Buy
+9,598
New +$207K ﹤0.01% 904

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HBK Investments's TBPH Position: Q2 2019 in Review

HBK Investments sold out of Theravance Biopharma (TBPH) in Q2 2019, closing a stake of 24,922 shares — an estimated $565K sold.

HBK Investments first reported a position in TBPH in Q2 2016 and held it in 2 quarters. The position peaked at $565K in Q1 2019. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2019.

  • HBK Investments reported no remaining Theravance Biopharma position as of Q2 2019 after selling out during the quarter.
  • HBK Investments sold 24,922 Theravance Biopharma shares in Q2 2019, an estimated $565K.
  • HBK Investments first reported a position in Theravance Biopharma in Q2 2016 and held it in 2 quarters.
  • HBK Investments's Theravance Biopharma position peaked at $565K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.